E. Richtig

发表

In vivo reflectance confocal microscopy: automated diagnostic image analysis of melanocytic skin tumours

R. Hofmann-Wellenhof, S. Koller, M. Wiltgen, 2011, Journal of the European Academy of Dermatology and Venereology : JEADV.

The anti–PD-1 antibody spartalizumab (S) in combination with dabrafenib (D) and trametinib (T) in previously untreated patients (pts) with advanced BRAF V600–mutant melanoma: Updated efficacy and safety from parts 1 and 2 of COMBI-I.

D. Schadendorf, K. Flaherty, P. Ascierto, 2019, Journal of Clinical Oncology.

Repigmentation after surgery of melanoma in a burn scar: dermoscopy as aid for the management decision.

R. Hofmann-Wellenhof, I. Zalaudek, V. Ahlgrimm-Siess, 2007, Dermatologic surgery : official publication for American Society for Dermatologic Surgery [et al.].

HGF-promoted motility in primary human melanocytes depends on CD44v6 regulated via NF-kappa B, Egr-1, and C/EBP-beta.

H. Kerl, E. Richtig, H. Schaider, 2010, The Journal of investigative dermatology.

Automated measurement of melanoma cross-sectional area.

R. Hofmann-Wellenhof, H. Kerl, E. Richtig, 1998, The American Journal of dermatopathology.

Calculated tumour volume as a prognostic parameter for survival in choroidal melanomas

E. Richtig, J. Smolle, G. Langmann, 2004, Eye.

Prospective, randomized, multicenter, double-blind placebo-controlled trial comparing adjuvant interferon alfa and isotretinoin with interferon alfa alone in stage IIA and IIB melanoma: European Cooperative Adjuvant Melanoma Treatment Study Group.

A. Steiner, H. Pehamberger, H. Soyer, 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

MUG Mel3 Cell Lines Reflect Heterogeneity in Melanoma and Represent a Robust Model for Melanoma in Pregnancy

E. Richtig, B. Rinner, Sabrina Riedl, 2021, International journal of molecular sciences.

Cutaneous Zosteriform Melanoma Metastases Arising After Herpes Zoster Infection: Case Report And Review Of The Literature

R. Hofmann-Wellenhof, I. Zalaudek, E. Richtig, 2003, Melanoma research.

Clinical Epidemiology of Invasive Cutaneous Malignant Melanoma in the Austrian Province Styria in the Years 2001–2003 and Its Relationship with Local Geographical, Meteorological and Economic Data

A. Berghold, H. Kerl, H. Denk, 2007, Dermatology.

Problems and challenges of predatory journals

W. Aberer, E. Richtig, G. Richtig, 2018, Journal of the European Academy of Dermatology and Venereology : JEADV.

A Retrospective Chart Review Study of Real-World Use of Talimogene Laherparepvec in Unresectable Stage IIIB–IVM1a Melanoma in Four European Countries

S. Haferkamp, E. Richtig, M. A. Huber, 2020, Advances in Therapy.

Unmasking of a primary desmoplastic melanoma tumour in the course of treatment of a metastatic disease with anti‐PD‐1 monoclonal antibody

R. Dummer, E. Richtig, S. Ferrone, 2019, Journal of the European Academy of Dermatology and Venereology : JEADV.

Combined PD-1, BRAF and MEK inhibition in advanced BRAF-mutant melanoma: safety run-in and biomarker cohorts of COMBI-i

D. Schadendorf, K. Flaherty, P. Ascierto, 2020, Nature Medicine.

Association of Stress Coping Strategies with Immunological Parameters in Melanoma Patients.

H. Kapfhammer, E. Richtig, M. D. Linder, 2016, Acta dermato-venereologica.

Should dermatologists go public? A skin cancer screening campaign at recreation centers.

R. Hofmann-Wellenhof, H. Soyer, H. Kerl, 2000, Archives of dermatology.

Adjuvant anti‐PD‐1 antibody treatment in stage III/IV melanoma: real‐world experience and health economic considerations

E. Richtig, H. Ostermann, V. Nguyen, 2021, Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG.

Noninvasive differentiation between mamillary eczema and Paget disease by in vivo reflectance confocal microscopy on the basis of two case reports

R. Hofmann-Wellenhof, V. Ahlgrimm-Siess, E. Richtig, 2011, The British journal of dermatology.

Profiles of chemokine receptors in melanocytic lesions: de novo expression of CXCR6 in melanoma.

M. Herlyn, K. Zatloukal, M. Asslaber, 2007, Human pathology.

Patterns of care and follow-up care of patients with uveal melanoma in German-speaking countries: a multinational survey of the German Dermatologic Cooperative Oncology Group (DeCOG)

A. Enk, C. Berking, S. Haferkamp, 2020, Journal of Cancer Research and Clinical Oncology.

Psychological Stress and Immunological Modulations in Early-stage Melanoma Patients.

A. Berghold, H. Kapfhammer, E. Richtig, 2015, Acta dermato-venereologica.

Sequencing of Ipilimumab Plus Nivolumab and Encorafenib Plus Binimetinib for Untreated BRAF-Mutated Metastatic Melanoma (SECOMBIT): A Randomized, Three-Arm, Open-Label Phase II Trial

D. Mallardo, P. Ascierto, R. Dummer, 2022, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Ocular Melanoma: Epidemiology, Clinical Presentation and Relationship with Dysplastic Nevi

E. Richtig, J. Smolle, G. Langmann, 2004, Ophthalmologica.

Impact of baseline serum lactate dehydrogenase concentration on the efficacy of pembrolizumab and ipilimumab in patients with advanced melanoma: data from KEYNOTE-006

N. Ibrahim, A. Ribas, C. Blank, 2017 .

Long‐term adherence to melanoma follow‐up examinations – a telephone survey

E. Richtig, G. Richtig, L. Koch, 2022, Journal of the European Academy of Dermatology and Venereology : JEADV.

Risk Factors of Subsequent Primary Melanomas in Austria

E. Richtig, R. Sunder-Plassmann, G. Fischer, 2019, JAMA dermatology.

Anaphylactic shock following peritumoral injection of patent blue in sentinel lymph node biopsy procedure.

W. Aberer, E. Richtig, B. Kränke, 2000, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.

Suction Drain Volume following Axillary Lymph Node Dissection for Melanoma—When to Remove Drains? A Retrospective Cohort Study

E. Richtig, L. Kamolz, P. Wurzer, 2022, Journal of personalized medicine.

Talimogene laherparepvec can initiate plasma cell invasion into infiltrated melanoma lesions – a case series

L. Cerroni, T. Deinlein, E. Richtig, 2020, Journal of the European Academy of Dermatology and Venereology : JEADV.

Clinical and Laboratory Investigations Local recurrence in melanoma in situ: influence of sex, age, site of involvement and therapeutic modalities

I. Zalaudek, H. Kerl, E. Richtig, 2003 .

Tinea capitis in early infancy treated with itraconazole: a pilot study

W. Weger, E. Richtig, B. Binder, 2009, Journal of the European Academy of Dermatology and Venereology : JEADV.

Immunotherapy with ipilimumab plus nivolumab in a stage IV melanoma patient during pregnancy.

A. Enk, D. Jäger, E. Richtig, 2018, European journal of cancer.

Assessment of changes in lentigo maligna during radiotherapy by in‐vivo reflectance confocal microscopy: a pilot study

R. Hofmann-Wellenhof, E. Richtig, R. Fink‐Puches, 2015, The British journal of dermatology.

Iris Freckles a Potential Biomarker for Chronic Sun Damage.

R. Hofmann-Wellenhof, I. Zalaudek, E. Richtig, 2017, Investigative ophthalmology & visual science.

New insights into oculodermal nevogenesis and proposal for a new iris nevus classification

I. Zalaudek, E. Richtig, G. Langmann, 2014, British Journal of Ophthalmology.

Autonomic nervous tone in vitiligo patients--a case-control study.

H. Kapfhammer, E. Richtig, P. Wolf, 2015, Acta dermato-venereologica.

Pregnancy as a driver for melanoma

R. Hofmann-Wellenhof, H. Soyer, E. Richtig, 2017, The British journal of dermatology.

Melanocytes, Organogenesis, and Angiogenesis: Evidence for More than a Pigment-Producing Capability of Melanocytes

R. Hofmann-Wellenhof, I. Zalaudek, M. Weger, 2019, Cells Tissues Organs.

Dermoscopy patterns of halo nevi.

R. Hofmann-Wellenhof, I. Zalaudek, A. Di Stefani, 2006, Archives of dermatology.

Function and Clinical Implications of Long Non-Coding RNAs in Melanoma

E. Richtig, M. Pichler, Tony Gutschner, 2017, International journal of molecular sciences.

Loss of Lymphotoxin Alpha-Expressing Memory B Cells Correlates with Metastasis of Human Primary Melanoma

K. Mertz, S. Wagner, J. Griss, 2021, Diagnostics.

Spatiotemporal Analysis of B Cell- and Antibody Secreting Cell-Subsets in Human Melanoma Reveals Metastasis-, Tumor Stage-, and Age-Associated Dynamics

K. Mertz, S. Wagner, J. Griss, 2021, Frontiers in Cell and Developmental Biology.

Higher psychological and psychovegetative strain in adolescents with atypical pigment naevi.

H. Kapfhammer, E. Richtig, A. Lvov, 2015, Acta dermato-venereologica.

Beyond the BRAFV600E hotspot: biology and clinical implications of rare BRAF gene mutations in melanoma patients

L. Kwong, E. Richtig, M. Pichler, 2017, The British journal of dermatology.

Usage and Distribution for Commercial Purposes Requires Written Permission. Two Case Reports of Rare Braf Mutations in Exon 11 and Exon 15 with Discussion of Potential Treatment Options

E. Richtig, H. Schaider, G. Richtig, 2022 .

BRAF mutation analysis of only one metastatic lesion can restrict the treatment of melanoma: a case report

C. Massone, S. Ugurel, E. Richtig, 2013, The British journal of dermatology.

Pretreatment metastatic growth rate determines clinical outcome of advanced melanoma patients treated with anti-PD-1 antibodies: a multicenter cohort study

C. Berking, C. Garbe, S. Kimeswenger, 2021, Journal for ImmunoTherapy of Cancer.

Serum levels of hepatocyte growth factor as a potential tumor marker in patients with malignant melanoma

A. Hauschild, U. Wehkamp, F. Egberts, 2016, Melanoma research.

The Importance of a Biopsychosocial Approach in Melanoma ResearchExperiences from a Single-center Multidisciplinary Melanoma Working Group in Middle-Europe.

H. Kapfhammer, E. Richtig, G. Richtig, 2016, Acta dermato-venereologica.

Outcomes by line of therapy and programmed death ligand 1 expression in patients with advanced melanoma treated with pembrolizumab or ipilimumab in KEYNOTE-006: A randomised clinical trial.

D. Schadendorf, A. Ribas, K. Emancipator, 2018, European journal of cancer.

Locoregional Cutaneous Metastases of Malignant Melanoma and their Management

H. Kerl, I. Wolf, E. Richtig, 2004, Dermatologic surgery : official publication for American Society for Dermatologic Surgery [et al.].

Partial response of metastatic mucosal melanoma after palliative chemotherapy with trofosfamide: a case report.

J. Becker, S. Ugurel, E. Richtig, 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Circulating Tumor DNA as a Marker for Treatment Response in Metastatic Melanoma Patients Using Next-Generation Sequencing—A Prospective Feasibility Study

I. Wolf, E. Richtig, M. Pichler, 2021, Cancers.

Body mass index may predict the response to ipilimumab in metastatic melanoma: An observational multi-centre study

I. Wolf, S. Pilz, E. Richtig, 2018, PloS one.

Testing and clinical implications for non‐V600 BRAF mutations in metastatic NRASmt melanoma

E. Richtig, M. Pichler, M. Grübler, 2017, The British journal of dermatology.

Adjuvant treatment with pegylated interferon α-2a versus low-dose interferon α-2a in patients with high-risk melanoma: a randomized phase III DeCOG trial.

C. Berking, A. Hauschild, D. Schadendorf, 2016, Annals of oncology : official journal of the European Society for Medical Oncology.

Patient acceptance and diagnostic utility of automated digital image analysis of pigmented skin lesions

R Hofmann-Wellenhof, R. Hofmann-Wellenhof, V. Ahlgrimm-Siess, 2012, Journal of the European Academy of Dermatology and Venereology : JEADV.

Circulating adhesion molecules as prognostic factors for cutaneous melanoma.

H. Kerl, H. Soyer, E. Richtig, 1997, Journal of the American Academy of Dermatology.

Temozolomide and interferon alpha 2b in metastatic melanoma stage IV.

R. Hofmann-Wellenhof, A. Seeber, A. Steiner, 2004, The British journal of dermatology.

Chemosensitivity-directed therapy compared to dacarbazine in chemo-naive advanced metastatic melanoma: a multicenter randomized phase-3 DeCOG trial

J. Utikal, C. Berking, D. Schadendorf, 2017, Oncotarget.

Diagnostic applicability of in vivo confocal laser scanning microscopy in melanocytic skin tumors.

Cesare Massone, Josef Smolle, Helmut Kerl, 2005, The Journal of investigative dermatology.

Ratio of marked and excised sentinel lymph nodes and scintigraphic appearance time in melanoma patients with negative sentinel lymph node.

I. Zalaudek, E. Richtig, A. Ott, 2010, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.

Analysis of clinical, dermoscopic and histopathological features of primary melanomas of patients with metastatic disease – a retrospective study at the Department of Dermatology, Medical University of Graz, 2000–2010

R. Hofmann-Wellenhof, C. Massone, E. Richtig, 2014, Journal of the European Academy of Dermatology and Venereology : JEADV.

Prevalence of nevi, atypical nevi, and lentigines in relation to tobacco smoking

I. Zalaudek, I. Wolf, E. Richtig, 2021, PloS one.

Does the time interval between sentinel lymph node biopsy and completion lymph node dissection affect outcome in malignant melanoma? A retrospective cohort study.

E. Richtig, D. Lumenta, F. Quehenberger, 2020, International journal of surgery.

Sensitivity and specificity of confocal laser‐scanning microscopy for in vivo diagnosis of malignant skin tumors

Josef Smolle, Hellmut Samonigg, Helmut Kerl, 2006, Cancer.

Treatment of Primary and Metastatic Multifocal Mucosal Melanoma of the Oral Cavity with Imatinib

R. Hofmann-Wellenhof, I. Zalaudek, I. Wolf, 2017, Case Reports in Oncology.

Organ‐ and treatment‐specific local response rates to systemic and local treatment modalities in stage IV melanoma

H. Kerl, E. Richtig, J. Smolle, 2005, The British journal of dermatology.

Patient-reported outcomes in KEYNOTE-006, a randomised study of pembrolizumab versus ipilimumab in patients with advanced melanoma.

W. Miller, N. Ibrahim, C. Robert, 2017, European journal of cancer.

Characterization of patients at high risk of melanoma in Austria

H. Pehamberger, S. Burgstaller-Muehlbacher, E. Richtig, 2016, The British journal of dermatology.

Primary mucosal melanomas of the nasal cavity and paranasal sinuses

E. Richtig, A. Beham, S. Regauer, 1998, APMIS : acta pathologica, microbiologica, et immunologica Scandinavica.

[Primary sinu-nasal melanomas. Clinical aspects, therapy and follow-up].

E. Richtig, J. Smolle, S. Regauer, 2002, Der Hautarzt; Zeitschrift fur Dermatologie, Venerologie, und verwandte Gebiete.

Commonly integrated epigenetic modifications of differentially expressed genes lead to adaptive resistance in cancer

E. Richtig, P. Duijf, D. Hoon, 2019, Epigenomics.

Topical imiquimod in the treatment of metastatic melanoma to skin.

H. Kerl, L. Cerroni, I. Wolf, 2003, Archives of dermatology.

The therapeutic landscape of advanced melanoma

E. Richtig, 2020, memo - Magazine of European Medical Oncology.

Assessing melanoma risk factors: how closely do patients and doctors agree?

R. Hofmann-Wellenhof, E. Richtig, R. Fink‐Puches, 2008, Public health.

Efficacy of superficial and deep regional hyperthermia combined with systemic chemotherapy and radiotherapy in metastatic melanoma

R. Hofmann-Wellenhof, I. Zalaudek, P. Rehak, 2003, Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG.

Response to the letter, “Underpowered conclusions can be potentially misleading with regards to the number of lymphoscintigraphy identified and surgically excised sentinel nodes in melanoma patients” by Nicholas C. Lee and Andrew J. Spillane

I. Zalaudek, E. Richtig, P. Komericki, 2011 .

Reflectance confocal microscopy in early diagnosis of cutaneous metastases of breast cancer.

R. Hofmann-Wellenhof, E. Richtig, A. Gerger, 2009, Gynecologic oncology.

The anti–PD-1 antibody spartalizumab in combination with dabrafenib and trametinib in advanced BRAF V600–mutant melanoma: Efficacy and safety findings from parts 1 and 2 of the Phase III COMBI-i trial.

D. Schadendorf, K. Flaherty, P. Ascierto, 2020 .

Proposal for a clinical–dermoscopic classification of scalp naevi

R. Hofmann-Wellenhof, I. Zalaudek, E. Richtig, 2014, The British journal of dermatology.

Frequency, clinical and dermoscopic features of benign papillomatous melanocytic naevi (Unna type)

R. Hofmann-Wellenhof, V. Ahlgrimm-Siess, E. Richtig, 2009, The British journal of dermatology.

Cardiac surgery for metastatic melanoma

E. Richtig, R. Zweiker, A. Aigelsreiter, 2014, Wiener klinische Wochenschrift.

Karnofsky performance status and lactate dehydrogenase predict the benefit of palliative whole-brain irradiation in patients with advanced intra- and extracranial metastases from malignant melanoma.

A. Berghold, E. Richtig, A. Avian, 2013, International journal of radiation oncology, biology, physics.

R. Hofmann-Wellenhof, I. Zalaudek, G. Argenziano, 2006, The British journal of dermatology.

In vivo confocal scanning laser microscopy of common naevi with globular, homogeneous and reticular pattern in dermoscopy

R. Hofmann-Wellenhof, C. Massone, S. Koller, 2008, The British journal of dermatology.

Reflectance confocal microscopy--state-of-art and research overview.

Rainer Hofmann-Wellenhof, Josef Smolle, Erika Richtig, 2009, Seminars in cutaneous medicine and surgery.

In vivo analysis of solar lentigines by reflectance confocal microscopy before and after Q-switched ruby laser treatment.

Rainer Hofmann-Wellenhof, Erika Richtig, Daisy Kopera, 2011, Acta dermato-venereologica.

Reflectance confocal microscopy of facial lentigo maligna and lentigo maligna melanoma: a preliminary study

R. Hofmann-Wellenhof, C. Massone, A. Scope, 2009, The British journal of dermatology.

In vivo confocal laser scanning microscopy of melanocytic skin tumours: diagnostic applicability using unselected tumour images

R. Hofmann-Wellenhof, U. Langsenlehner, H. Samonigg, 2008, The British journal of dermatology.

Follow‐up of actinic keratoses after shave biopsy by in‐vivo reflectance confocal microscopy – a pilot study

R. Hofmann-Wellenhof, S. Koller, V. Ahlgrimm-Siess, 2010, Journal of the European Academy of Dermatology and Venereology : JEADV.

Percutaneous hepatic perfusion (PHP) with melphalan for patients with ocular melanoma liver metastases: Preliminary results of FOCUS (PHP-OCM-301/301A) phase III trial.

A. Gesierich, A. Ejaz, R. Dummer, 2021 .

Real-life use of talimogene laherparepvec (T-VEC) in melanoma patients in centers in Austria, Switzerland and Germany

E. Richtig, O. Michielin, C. Hoeller, 2021, Journal for ImmunoTherapy of Cancer.

Temozolomide and interferon α2b in metastatic melanoma stage IV

R. Hofmann-Wellenhof, A. Seeber, A. Steiner, 2004 .

Primitive neuroectodermal tumor arising in the skin. Differentiation from neuroendocrine carcinoma of the skin.

H. Popper, E. Richtig, J. Smolle, 1992, Dermatology.

Real life use of talimogene laherparepvec in melanoma in centers in Austria and Switzerland

E. Richtig, O. Michielin, C. Hoeller, 2019, Annals of Oncology.

Melanoma Markers in Marathon Runners: Increase with Sun Exposure and Physical Strain

R. Hofmann-Wellenhof, H. Kerl, H. Lackner, 2008, Dermatology.

Malignant melanoma in marathon runners.

R. Hofmann-Wellenhof, H. Kerl, H. Soyer, 2006, Archives of dermatology.

Awareness of predatory journals and open access among medical oncologists: results of an online survey

E. Richtig, C. Oing, C. Zielinski, 2019, ESMO Open.

Knowledge and Influence of Predatory Journals in Dermatology: A Pan-Austrian Survey.

A. Steiner, T. Deinlein, W. Hoetzenecker, 2019, Acta dermato-venereologica.

The importance of the given history in the differential diagnosis of blue nodules.

R. Hofmann-Wellenhof, I. Zalaudek, E. Richtig, 2015, Journal of American Academy of Dermatology.

Non-invasive imaging of tissue PO2 in malignant melanoma of the skin

R. Hofmann-Wellenhof, H. Kerl, E. Richtig, 2006, Melanoma research.

Surveillance of patients with conjunctival melanoma in German-speaking countries: A multinational survey of the German dermatologic cooperative oncology group.

A. Enk, C. Berking, S. Haferkamp, 2020, European journal of cancer.

Knowledge and Perception of Melanocytic Nevi and Sunburn in Young Children

R. Hofmann-Wellenhof, E. Richtig, Michael Trapp, 2009, Pediatric dermatology.

Proton pump inhibitors negatively impact survival of PD-1 inhibitor based therapies in metastatic melanoma patients

D. Hanahan, G. Coukos, U. Dafni, 2018, Annals of Oncology.

KEYNOTE-006 study of pembrolizumab (pembro) versus ipilimumab (ipi) for advanced melanoma: Efficacy by PD-L1 expression and line of therapy.

K. Emancipator, C. Blank, I. Puzanov, 2016 .

Erythema nodosum‐like lesions during BRAF inhibitor therapy: Report on 16 new cases and review of the literature

C. Berking, K. Kähler, S. Ugurel, 2015, Journal of the European Academy of Dermatology and Venereology : JEADV.

Response of patients with metastatic uveal melanoma to combined treatment with fotemustine and sorafenib

E. Richtig, G. Schwantzer, W. Wackernagel, 2014, Acta ophthalmologica.

Exanthema with eosinopenia

W. Aberer, E. Richtig, B. Kränke, 2002, Allergy.

Diagnostic image analysis of malignant melanoma in in vivo confocal laser‐scanning microscopy: a preliminary study

Rainer Hofmann-Wellenhof, Josef Smolle, Michael Horn, 2008, Skin research and technology : official journal of International Society for Bioengineering and the Skin (ISBS) [and] International Society for Digital Imaging of Skin (ISDIS) [and] International Society for Skin Imaging.

A Unifying Concept of Uveal Pigment Cell Distribution and Dissemination Based on an Animal Model: Insights into Ocular Melanogenesis

R. Hofmann-Wellenhof, I. Zalaudek, E. Richtig, 2016, Cells Tissues Organs.

Nivolumab for locally advanced and metastatic cutaneous squamous cell carcinoma (NIVOSQUACS study)—Phase II data covering impact of concomitant haematological malignancies

E. Richtig, V. Nguyen, M. Laimer, 2023, Journal of the European Academy of Dermatology and Venereology : JEADV.

First-Line, Fixed-Duration Nivolumab Plus Ipilimumab Followed by Nivolumab in Clinically Diverse Patient Populations With Unresectable Stage III or IV Melanoma: CheckMate 401

P. Ascierto, R. Dummer, M. Del Vecchio, 2023, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Interferon for melanoma.

E. Richtig, G. Langmann, 2010, Ophthalmology.

Clinical and Laboratory Investigations Local recurrence in melanoma in situ: influence of sex, age, site of involvement and therapeutic modalities

I. Zalaudek, H. Kerl, E. Richtig, 2003 .

Complete Recovery of a Wide Local Reaction by the Use of Dexrazoxane 72 Hours after Epirubicin Extravasation: Case Report and Review of the Literature

E. Richtig, T. Bauernhofer, E. Petru, 2014, Dermatology.

Abstract CT182: The anti-PD-1 antibody spartalizumab (PDR001) in combination with dabrafenib and trametinib in previously untreated patients with advancedBRAFV600-mutant melanoma: First efficacy, safety, and biomarker findings from the part 2 biomarker cohort of COMBi-i

D. Schadendorf, P. Ascierto, R. Dummer, 2018, Clinical Trials.

Coping strategies in melanoma patients.

E. Richtig, F. Sampogna, M. D. Linder, 2012, Acta dermato-venereologica.

Real‐world outcomes using PD‐1 antibodies and BRAF + MEK inhibitors for adjuvant melanoma treatment from 39 skin cancer centers in Germany, Austria and Switzerland

S. Haferkamp, K. Kähler, W. Peitsch, 2022, Journal of the European Academy of Dermatology and Venereology : JEADV.

Natural history of invasive cutaneous melanoma in Styria, Austria 2001–2003

A. Berghold, H. Kerl, E. Richtig, 2007, Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG.

Pregnancy as a driver for melanoma

E. Richtig, L. Byrom, I. Wolf, 2017, British Journal of Dermatology.

Temozolomide and interferon α2b in metastatic melanoma stage IV

R. Hofmann-Wellenhof, A. Seeber, A. Steiner, 2004 .

Digital image enhancement for in vivo laser scanning microscopy

Josef Smolle, Helmut Kerl, Martin J Gruber, 2005, Skin research and technology : official journal of International Society for Bioengineering and the Skin (ISBS) [and] International Society for Digital Imaging of Skin (ISDIS) [and] International Society for Skin Imaging.

Assessing the Performance of a Novel Stool-Based Microbiome Test That Predicts Response to First Line Immune Checkpoint Inhibitors in Multiple Cancer Types

A. Valipour, E. Richtig, G. Absenger, 2023, Cancers.

117P BiomeOne: Multi-centric validation of a novel microbiome-based biomarker to predict response to cancer immunotherapy

E. Richtig, G. Absenger, Ivan Ochsenius Robinson, 2022, Annals of Oncology.

[Safety and efficacy of interferon alfa-2b in the adjuvant treatment of uveal melanoma].

E. Richtig, J. Smolle, G. Langmann, 2006, Der Ophthalmologe : Zeitschrift der Deutschen Ophthalmologischen Gesellschaft.

Sequential immunotherapy and targeted therapy for metastatic BRAF V600 mutated melanoma: 4-year survival and biomarkers evaluation from the phase II SECOMBIT trial

D. Mallardo, P. Ascierto, M. Del Vecchio, 2024, Nature communications.

Predatory journals: Perception, impact and use of Beall’s list by the scientific community–A bibliometric big data study

E. Richtig, M. Maurer, F. Siebenhaar, 2023, PloS one.

Knowledge and Influence of Predatory Journals in Dermatology: A Pan-Austrian Survey.

A. Steiner, T. Deinlein, W. Hoetzenecker, 2019, Acta dermato-venereologica.